Foghorn Therapeutics (FHTX) Operating Margin (2020 - 2026)
Foghorn Therapeutics' quarterly Operating Margin came in at 660.33% in Q1 2026, down 27537.0% year-on-year from N/an in Q1 2025, and down 155.72% quarter-over-quarter from 258.22% in Q4 2025.
Foghorn Therapeutics has reported Operating Margin for 7 years, with the latest figure at 660.33% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 27537.0% year-over-year to 660.33%; the trailing twelve-month figure through Mar 2026 stood at 301.34% (up 11307.0% YoY), and the FY2025 full-year result was 279.49%, up 17481.0% from the prior year.
- Operating Margin for Q1 2026 stood at 660.33%, down from 258.22% in the prior quarter.
- The five-year high for Operating Margin was 97.73% in Q3 2023, with the low at 840.51% in Q4 2024.
- Average Operating Margin over 5 years is 481.59%, with a median of 441.29% recorded in 2023.
- Year-over-year, Operating Margin soared 6362525 bps in 2022 and plunged 39922 bps in 2024.
- Tracing FHTX's Operating Margin over 5 years: stood at 762.09% in 2022, then soared by 42 bps to 441.29% in 2023, then plunged by 90 bps to 840.51% in 2024, then jumped by 69 bps to 258.22% in 2025, then sank by 156 bps to 660.33% in 2026.
- The last three Operating Margin figures came in at 660.33% (Q1 2026), 258.22% (Q4 2025), and 226.92% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - | -660.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -660.33% |
| Dec 31, 2025 | -258.22% |
| Sep 30, 2025 | -226.92% |
| Jun 30, 2025 | -279.17% |
| Mar 31, 2025 | -384.96% |
| Dec 31, 2024 | -840.51% |
| Sep 30, 2024 | -305.48% |
| Jun 30, 2024 | -386.64% |
| Mar 31, 2024 | -558.30% |
| Dec 31, 2023 | -441.29% |
| Sep 30, 2023 | -97.73% |
| Jun 30, 2023 | -572.42% |
| Mar 31, 2023 | -627.56% |
| Dec 31, 2022 | -762.09% |
| Sep 30, 2022 | -425.97% |
| Jun 30, 2022 | -650.07% |
| Mar 31, 2022 | -709.29% |
| Dec 31, 2021 | -3,938.57% |
| Sep 30, 2021 | -64,051.22% |
| Jun 30, 2021 | -8,337.28% |
| Mar 31, 2021 | -8,087.41% |
| Dec 31, 2020 | -8,278.49% |
| Sep 30, 2020 | -10,329.05% |